1. Home
  2. NBIX vs NWS Comparison

NBIX vs NWS Comparison

Compare NBIX & NWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

N/A

Current Price

$155.12

Market Cap

15.5B

Sector

Health Care

ML Signal

N/A

Logo News Corporation Class B

NWS

News Corporation Class B

N/A

Current Price

$33.88

Market Cap

17.9B

ML Signal

N/A

Company Overview

Basic Information
Metric
NBIX
NWS
Founded
1992
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
15.5B
17.9B
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
NBIX
NWS
Price
$155.12
$33.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
22
4
Target Price
$180.91
$38.18
AVG Volume (30 Days)
1.1M
1.0M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
0.66%
EPS Growth
41.95
N/A
EPS
3.30
1.03
Revenue
$161,626,000.00
$9,028,000,000.00
Revenue This Year
$24.73
$6.06
Revenue Next Year
$13.14
$3.25
P/E Ratio
$47.95
$33.66
Revenue Growth
977.51
6.81
52 Week Low
$122.14
$25.49
52 Week High
$186.12
$35.76

Technical Indicators

Market Signals
Indicator
NBIX
NWS
Relative Strength Index (RSI) 48.44 61.05
Support Level $153.96 $29.48
Resistance Level $161.29 $35.54
Average True Range (ATR) 3.58 0.73
MACD 0.90 -0.07
Stochastic Oscillator 77.56 65.89

Price Performance

Historical Comparison
NBIX
NWS

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About NWS News Corporation Class B

News Corporation is a diversified media and information services conglomerate with significant presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings platform in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

Share on Social Networks: